[Ip-health] MSF responds to least-developed country IP exemption deal

Joanna Keenan joanna.l.keenan at gmail.com
Tue Nov 3 08:18:26 PST 2015


MSF responds to least-developed country IP exemption deal

*http://www.msfaccess.org/about-us/media-room/press-releases/msf-responds-least-developed-country-ip-exemption-deal
<http://www.msfaccess.org/about-us/media-room/press-releases/msf-responds-least-developed-country-ip-exemption-deal>
3 November 2015, Geneva* - Information has emerged that the world's poorest
countries - those classified as least-developed countries (LDCs) - have
been granted a 17 year exemption from implementing intellectual property
provisions, such as patents, on medicines. LDCs had wanted and MSF had
advocated
<http://www.msfaccess.org/about-us/media-room/press-releases/msf-response-ec-announcement-ldc-extension-wto-ip-rules>
for an exemption to be granted for as long as countries were classified as
a LDC.

MSF quote in response:
“For the world’s poorest countries to be granted only a 17 year exemption
on implementing intellectual property for pharmaceuticals is essentially
kicking the can down the road, forcing this difficult debate to resurface.
Unless least-developed countries are granted an exemption until they
graduate from their status as LDCs, they’ll have to keep revisiting this
debate.

“The mixed bag of support for an indefinite LDC exemption at the WTO had
the European Union in support; the Global Fund to Fight AIDS, Tuberculosis
and Malaria unfortunately sitting by silently; and the United States
government vehemently opposing. We applaud the European Commission’s
efforts to fully accept the LDC request, and hope the Commission continues
to put the needs of people first. It’s baffling that the Global Fund did
not stand up in support of people’s access to low-cost generic medicines
for the world’s poorest countries. The US has denied the world’s poorest
countries the security and peace of mind of an exemption until they
graduate as a LDC. The deal shows that the US government is more interested
in backing the commercial interests of multinational drug companies in lieu
of doing what’s fair for sick people in the world’s poorest countries.”

- Rohit Malpani, Director Policy and Analysis, Médecins Sans Frontières
Access Campaign.


Joanna Keenan
Press Officer
Médecins Sans Frontières - Access Campaign
P: +41 22 849 87 45
M: +41 79 203 13 02
E: joanna.keenan[at]geneva.msf.org
T: @joanna_keenan

msfaccess.org
twitter.com/MSF_access
facebook.com/MSFaccess



More information about the Ip-health mailing list